A new blood test for Alzheimer's disease has been developed, capable of detecting key biomarkers associated with the disease, and potentially identifying it at a preclinical stage.

The blood test targets abnormal levels of amyloid or Tau proteins, offering a less invasive and more cost-effective alternative to traditional diagnostic methods like spinal taps and PET scans.

With Alzheimer's cases estimated at 50 million globally, the test could revolutionize screening and diagnostic processes, making them more accessible to the aging population.

The blood test's utility is currently tied to the progress in Alzheimer's treatments, as existing treatments only modestly slow disease progression.

The future of Alzheimer's management could be shaped by the combination of effective treatments and the new blood test, but the emphasis currently is on treatment development before large-scale screening is implemented.